Adverse events to be put in Cymbalta and Teveten

Published: 2013-05-13 06:56:00

Updated: 2013-05-13 06:56:00

The Ministry of Food and Drug Safety (MFDS) said on Thursday that it instructed pharmaceutical companies to add the adverse events to the instructions of two medicinal products. Among the relevant products are Lilly’s Cymbalta (dulocetine) and Handok Pharm’s Teveten (eprosartan).

The move came...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK